Evidence map›Paper›PMID 35486441›Full record

ArticleJournal of cosmetic dermatology2022

Designing topical hyaluronic acid technology-Size does matter….

Alan D Widgerow, Mary E Ziegler, John A Garruto, Deanne Mraz Robinson, Melanie D Palm, Janelle H Vega, Michaela Bell

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cosmetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Multicenter evaluation of a topical hyaluronic acid serum.Journal of cosmetic dermatology · 2022
    Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Alan D WidgerowCenter for Tissue Engineering, Department of Plastic Surgery, University of California, Irvine, Irvine, California, USA.ORCID https://orcid.org/0000-0002-5705-8073
Mary E ZieglerCenter for Tissue Engineering, Department of Plastic Surgery, University of California, Irvine, Irvine, California, USA.
John A GarrutoAlastin, A Galderma Company, Fort Worth, Texas, USA.
Deanne Mraz RobinsonModern Dermatology, Westport, Connecticut, USA.
Melanie D PalmArt of Skin, Solana Beach, California, USA.
Janelle H VegaMayoral Dermatology, Miami, Florida, USA.
Michaela BellAlastin, A Galderma Company, Fort Worth, Texas, USA.ORCID https://orcid.org/0000-0003-4662-7274
Galderma (United States) · USUniversity of California, Irvine · USDade County Medical Examiner Department · USSkin Cancer Foundation · USYale University · US

Funding

Alastin, a Galderma Company
6 · The paper itself

Abstract

introductionHyaluronic acid (HA) plays an important role in cellular and extracellular matrix (ECM) homeostasis. Recent studies demonstrate that low molecular weight (MW) HA has pro-inflammatory characteristics while high MW HA is considered anti-inflammatory and regenerative. In formulating a topical HA product, the possibility of creating a focused high MW HA technology was posed, combining external surface high MW HA constituents with active agents promoting fibroblast production of high MW in the depths of the dermis.

methodsHuman dermal fibroblasts and keratinocytes were treated with various agents, and RNA sequencing (RNA-seq) was conducted to identify genes involved in HA synthesis. HA production by fibroblasts was assessed by collecting the culture supernatant, concentrating the protein, and conducting polyacrylamide gel electrophoresis (PAGE). The gel was stained with Stains-All to identify bands relative to known HA products of different MWs. Subsequently, the supernatants were treated with hyaluronidase to confirm the bands corresponded to HA.

resultsThe RNA-seq results revealed a variety of agents upregulated HA-related genes. However, a potent upregulation of HA synthesis gene was observed by hexapeptide-11 in the keratinocytes and a newly identified proprietary octapeptide in the fibroblasts. PAGE demonstrated not only robust production of HA by octapeptide, but significantly, the HA produced was ~2 Mega Daltons in size. Octapeptide was the most potent stimulator among the tested agents.

conclusionComprehensive in vitro testing identified a group of active agents that stimulated high MW HA production. This novel approach to HA topical application with exclusively high MW HA production should maximize hydration capacity while encouraging regenerative activity within the ECM. Multi-center trials are underway.

Indexed as

Hyaluronic AcidHyaluronoglucosaminidaseFibroblastsHumansMolecular WeightTechnologyHyaluronic AcidHyaluronoglucosaminidasehigh molecular weight HAhyaluronic acidhydrationoctapeptide

Identifiers

PMID35486441
PMCPMC9540682
OpenAlexW4225128771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.